Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


C-suite reality: how to resource your next product when it competes with your lead

This article was originally published in Scrip

Executive Summary

A bovine extracted product, or a human recombinant one? The choice isn't that obvious, especially if neither product has human proof of concept and the bovine product is less clinically advanced. This is the real dilemma that AM-Pharma faced in 2011, as chief executive officer Erik van den Berg explains to Mike Ward. In the end, AM raised nearly €30m and was able to forge ahead with the market's preferred product. But the case illustrates that for smaller companies, strategy decides between the best available options, not between ideal ones.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts